Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Oct 30, 2026
Reporting period
Not applicable
Filed with the SEC
Nov 4, 2026
CFOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001706176-26-000007
Filed / recorded
Nov 4, 2026, 12:26 AM UTC
Added to OQRO
Nov 4, 2026, 12:28 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
LENZ Therapeutics, Inc.
Issuer CIK
1815776
Ticker
LENZ
Reporting person
Daniel R. Chevallard
Relationship
Officer
Officer title
Chief Financial Officer
Security
Stock Option (right to buy)
Table
Derivative (Table II)
Transaction date
Oct 30, 2026
Transaction code
A
Shares / units
652,063
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
652,063
Ownership form
Direct
Amendment
No
Footnotes from the filing
Subject to the Reporting Person serving as the Issuer's Interim President and CEO through each applicable date, the shares subject to the option shall vest in four equal tranches, as follows: 25% of the shares subject to the option shall commence vesting on November 1, 2026 and vest in full on November 1, 2027; 25% of the shares subject to the option shall commence vesting on February 1, 2027 and vest in full on February 1, 2028; 25% of the shares subject to the option shall commence vesting on May 1, 2027 and vest in full on May 1, 2028; 25% of the shares subject to the option shall commence vesting on August 1, 2027 and vest in full on August 1, 2028. If the Reporting Person ceases to serve as the Issuer's Interim President and CEO for any reason, any tranche for which the vesting commencement date has not yet occurred will be forfeited, and any tranche for which the vesting commencement date has occurred will remain eligible to vest.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.